The D, and D, classification of dopamine receptor subtypes in brain was initially based on the response of adenylate cyclase in rat striatal homogenates to dopaminergic ligands (Kebabian and Came, 1979; Stoof and Kebabian, 198 1) . Corroboration of this D, and D, receptor dichotomy by receptor binding methods has been made possible by the development of D,-and D,-selective radioligands. For example, radioligand binding assays for the D, receptor (Creese and Snyder, 1975; Seeman et al., 1975; Creese et al., 1977) have widened our knowledge of D, receptors, including their regulation and function in brain (Seeman, 1980; Creese et al., 1983) . Quantitative autoradiography with these D,-selective compounds, especially 3H-spiperone (Palacios et al., 198 l) , has produced pharmacologically defined, quantitative maps of the D, receptor distribution in brain (Neve et al., 1984; Altar et al., 1985a, b) .
Only recently has a radioligand binding assay for the D, receptor become available. Iorio and colleagues (1983) and Hyttel (1983 Hyttel ( , 1984 demonstrated that SCH 23390 [R-(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-lH-3-benzazepin-7-o1 hemimaleate] is a selective antagonist of the stimulation by dopamine of the adenylate cyclase of rat striatal membranes. The tritiated form of SCH 23390 was subsequently shown to selectively label the D, receptor of rat striatal membranes with high affinity (& value of 300-400 PM) (Billard et al., 1984) .
Structure-activity studies by Kebabian and colleagues (Itoh et al., 1984; Sidhu and Kebabian, 1985) and by O'Boyle and Waddington (1985) have shown that the 7-Cl, but not N-methyl, substituent of SCH 23390 is crucial for its D,-antagonist activity. Replacing the chlorine with lZ51 preserved in racemic form the D, selectivity and augmented the specific activity of SCH 23982 (Sidhu and Kebabian, 1985) . The iodinated form of the active (+)-enantiomer of SCH 23390, R(+)-8-1251-iodo-7-hydroxy-2,3,4,5-tetrahydro-3-methyl-5-phenyl-lH-3-benzazepine, or 1251-SCH 23982 (Fig. l) , has since been made available from DuPont-NEN (Boston, MA). We have used *251-SCH 23982 to label the D, receptor in brain sections and, with quantitative receptor autoradiography, to characterize the binding affinity, capacity, and pharmacological specificity of this receptor throughout the basal ganglia. Using **SI-SCH 23982, we also show for the first time the presence of virtually all brain D, binding sites on intrinsic striatal neurons and striatonigral neurons and the discrete localization of D, sites in the substantia nigra.
Materials and Methods
Chemical lesioning techniques. Male albino rats (MbFSD, obtained from Marland Farms. Hewitt. NJ), each weizhinz 220-240 am. were given free access to food and water and were housed in a; animal vivarium (2 l-24°C) maintained under a 12 hr light : dark cycle. Twelve rats received an intrastriatal injection of 70 or 125 nmol quinolinic acid (Sigma Chem. Co., St. Louis, MO) dissolved in 0.6 or 1 .O pl, respectively, of sterile saline. Quinolinic acid was injected to destroy neurons whose cell bodies are intrinsic to the striatum (Schwartz et al., 1982 (Schwartz et al., , 1984 . Injections were made with a syringe microburet (Micro-Metric Instruments Co., Cleveland, OH) and were delivered during 2 min via a 32 gauge stainless steel cannula that terminated in the central caudateputamen [A = 8.0; L = 2.4; V = -4.4 mm, according to the atlas of Kiinig and Klippel (1967) ]. The cannula was withdrawn 5 min after the end of the infusion.
In another group of 5 rats, 6 pg of the selective dopamine neurotoxin, 6-hydroxydopamine (Ungerstedt, 1968,197 1; Uretsky and Iversen, 1970; Breese and Traylor, 1971 ) (Sigma Chem. Co., St. Louis, MO), was injected into the substantia nigra (A = 2.4; L = 1.0; V = 7.8 mm) 30 min after a 15 mg/kg i.p. (5 ml/kg sterile saline) injection of the norepinephrine reuptake blocker desmethylimipramine (Merrill-Dow, Cincinnati, OH) dissolved in distilled water. The desmethylimipramine was injected to spare noradrenergic neurons from 6-hydroxydopamine toxicity by retarding the uptake of the toxin by central noradrenergic neurons (Breese and Traylor, 197 1) . The 6-hydroxydopamine was dissolved in 1.0 ~1 of sterile saline containing 0.1% ascorbic acid (Ungerstedt, 1971) . The 6-hydroxydopamine was injected during 5 min via a 32 gauge cannula whose beveled tip was directed caudally. The cannula was removed 5 min after the end of the infusion.
All lesioned animals were killed by cervical decapitation 7 d after surgery. Maximal degeneration of intrinsic striatal cells (Schwartz et al., 1982 (Schwartz et al., , 1984 and dopaminergic cells of the substantia nigra (Hiikfelt and Ungerstedt, 1973; Altar et al., 1984a) occurs 7 days after the respective lesioning technique. The extent of dopamine denervation was assessed by the depletion of dopamine in the caudoputamen of the injected (left) hemisphere compared with the uninjected (right) caudoputamen. Dopamine was measured by gas chromatography with mass fragmentography (GC/MF) (Wood, 1982) .
Brain matrix autoradiography. The brains of the lesioned rats were frozen in isopentane at -10 to -20°C. Consecutive 15 firn coronal or sagittal sections were cut on a cryostat (Hacker Instruments, Clifton, NJ) at -12°C. For analysis of 1251-SCH 23982 binding to the striatum of intact animals, coronal sections were cut from a block of rat forebrain located 8.7-9.5 mm anterior to the interaural plane (K&rig and Klippel, 1967) . Coronal sections that were used in the saturation or pharmacological competition experiments were cut from a "brain matrix" of 4 adjacently frozen brain hemispheres (Altar, 1987) . After removal from the calvarium, each brain was rinsed in ice-cold 0.9% NaCl, blotted dry, and placed on a metal block. Coronal sections were made rostra1 and caudal to the region of interest with a tissue slicer blade (Thomas Scientific, Philadelphia, PA). The rostra1 section decreased the number of cryostat cuts required to reach the area of interest, and the caudal section provided a flat surface for mounting the brain to the cryostat chuck. To facilitate alignment of the 4 brain hemispheres in the rostrocaudal dimension and to create greater surface areas to freeze 1 hemisphere to the next, sagittal cuts were made about 2 mm from the most lateral extent of the neocortex. This cut exposed only the lateral aspect of the hippocampus and the surrounding neocortex. Each brain was bisected midsagittally. The right halves of the 4 brains were stacked next to one another, as were the left halves, and laid on the metal block with their ventral surfaces upward. The ventral surfaces of the brains were frozen with a 15 set exposure to a cryogenic aerosol spray (Lemer Laboratories, New Haven, CT). The brain assembly, or "matrix," was flipped over and the dorsal surface was sprayed for 15 sec. The brain matrix was frozen in isopentane at -20°C mounted on a cryostat chuck, and sectioned in the coronal dimension. Brain matrix autoradiography with a matrix of 4 hemispheres decreased the amount of cryostat cutting by 751 and decreased the work involved in all subsequent autoradiography procedures.
Sag&al views of lz51-SCH 23982 binding to the substantia nigra and striatum were obtained with tissue located 3.0-5.0 mm lateral to the midline (Paxinos and Watson, 1982) . Horizontal sections were collected (Paxinos and Watson, 1982) . Boxes define regions in which Y-SCH 23982 binding was quantified. Abbreviations:
C, central third of the substantia nigra; C/au, claustrum; CP, caudateputamen; EN, entopeduncular nucleus; FC, layer 6 of frontal cortex; ZC, internal capsule; L, lateral third of the SN, M, medial third of the SN, NA, nucleus accumbens; SN, substantia nigra, pars reticulata; OT, olfactory tubercle.
through the substantia nigra and caudoputamen. The individually cut brain sections were thawed onto gelatin-coated microscope slides and stored at -15°C in a humidified microscope slide box for 1 or 2 days (Herkenham and Pert, 1982) .
12sZ-SCH 23982 binding assay. The sections were thawed on a slide warmer, air-dried for 10 min, and laid horizontally on a %-in.-thick aluminum plate at 23°C. Each section was covered by 175 ~1 of a 50 mM, pH 7.4 (at 23°C) Tris buffer. The temperature and pH employed were very close to the optimal values for )H-SCH 23390 binding (Schulz et al., 1985) . The buffer contained 120 mM NaCI, 5 mM KCl, 2 mM CaCl,, 1 mM MgCl, (Sidhu and Kebabian, 1985) , and 2-770 PM lZsI-SCH 23982 (2200 Ci/mmol) (DuPont-NEN, Boston). Nonspecific binding was determined in alternate sections with 5 PM cis-flupenthixol (Hyttel, 1978; Murrin, 1983) .
For the displacement experiments, sections were coincubated with 1251-SCH 23982 and one of 7-12 concentrations of either SCH 23390 Autoradiography. The slides were apposed for 18 hr to 3H-Ultrofilm (LKB, Bromma, Sweden) in a 3-layered, desiccant-containing autoradiography cassette. Included with each piece of film were 6 15-pm-thick standards cut from homogenized, centrifuged (30 set x 50 x g), and frozen rat brain pastes (Neve et al., 1984) to which were added lZ51-SCH 23982 in concentrations ranging from 39,000 to 1,200,OOO dpm/ mg protein, or the equivalent of 8-253 fmol SCH 23982/mg protein.
The protein content of representative standards was measured by the method of Lowry et al. ( 195 1) . The equivalent SCH 23982 concentration of each standard was calculated on the basis of the specific activity of 12Sl-SCH 23982 used in the binding assays.
Under darkroom illumination, the autoradiographs were developed for 3% min in Kodak D-19 and exposed to Kodak indicator stop (30 set), Kodak fixer (4 min), cold tap water (10 min), and room-temperature air (1 hr) to dry.
Digital subtraction autoradiography. The amount of SCH 23982 bound in the brain regions illustrated in Figure 2 was quantified with a com- 'p < 0.05. dp < 0.01 vs medial substantia nigra; Dunnett's t test.
cinanserin, puter-assisted image analyzer (EyeCom II, Spatial Data Systems, Melbourne, FL). The logit-log gray value-to-concentration conversions (Snowhill and Boast, 1986 ) and the quantitation of iodinated ligand concentrations with the use of lz51 standards (Israel et al., 1984; Rainbow et al., 1984) have been described. The SCH 23982 concentrations in the original sections were quantitatively represented in "linearized" computer images in which a new set of gray values was computed and displayed for each digitized autoradiograph.
The new gray values represented lZ51-SCH 23982 binding in each image as a linear function of the equivalent concentration of SCH 23982. The techniques of linearization and visualizations of specific ligand binding by digital subtraction autoradiography have been described (Altar et al., 1984b (Altar et al., , 1985a . Briefly, the gray values in the digitized image can be converted to new gray values that are linearly related to 'Z51-SCH 23982 concentration. Areas of maximal binding are converted to the darkest (black) gray values, and areas of minimal binding are converted to the lightest (white) gray values. Importantly, all in-between gray values represent 1251-SCH (Bliss and James, 1966) . IC,, and Hill (nH) values were calculated by log&log analysis (Rodbard and Lewald, 1970) . Differences in 1251-SCH 23982 concentrations between brain hemispheres in the lesion experiments were calculated with the paired t test.
Results
As viewed in sagittal or horizontal section, the total binding of L2SI-SCH 23982 was almost exclusively localized to the striatal complex (caudoputamen, nucleus accumbens, olfactory tubercle) and substantia nigra (Fig. 3) . Moderate amounts of binding were present in the entopeduncular nucleus and less binding was found in the claustrum and sixth layer of the neocortex. A similar pattern of specific binding was observed in the striatal complex in coronal sections (Fig. 5 ) and in subtracted images of specific binding of sagittal and horizontal sections (data not shown). Notably, specific 1251-SCH 23982 binding was absent in the ventral tegmental area (data not shown, but see Fig. 5 ).
lZSI-SCH 23982 bound with high affinity to the striatal complex and substantia nigra ( Table 1) . The concentrations of binding sites were greatest in the medial substantia nigra (B,,, value of 176 fmol/mg protein), which exceeded by at least 50% the concentrations of D, sites in the lateral substantia nigra or in any region of the striatal complex Mnax values of 65-85 fmol/mg protein).
The displacement of 1251-SCH 23982 by unlabeled compounds (5 PM each) was quantified in 7 regions of sagittal sections. lZ51-SCH 23982 binding to the striatal complex and entopeduncular nucleus was displaced equally (73-86%) by cis-flupenthixol and by the selective D, agonist SKF 38393 (Table 2) (Table 1) . lZSI-SCH 23982 binding to the internal capsule or frontal cortex was displaced only 37-39%, but again equally by cis-flupenthixol and SKF 38393 and insignificantly by cinanserin (Table 2) , I-sulpiride, or LY 17 155 5 (data not shown).
In coronal sections, SCH 23390 was the most potent compound tested against lZ51-SCH 23982, occupying the D, site with an IC,, value of 95-190 PM (Table 3) . SCH 23390 displaced lZ51-SCH 23982 in a biphasic manner from sites in the caudateputamen (Fig. 4) , and consistently with Hill coefficients less than 1.0 (Table 3) (Table 3) . (I)-Sulpiride and LY 171555 displaced lZ51-SCH 23982 only at concentrations of 10 PM or above and cinanserin produced no displacement at concentrations as high as 2 FM (Fig. 4; Table 3 ).
Intrastriatal injections of 125 nmol quinolinic acid produced an 87% decrease in the concentration of D, sites in the caudateputamen and a 47% decrease in the substantia nigra (Table 4) . The loss of D, binding in the caudoputamen was generally widespread at the anterior-posterior level where the injection was made but never included the nucleus accumbens or complete rostral<audal extent of the caudoputamen. D, concentrations were decreased by 58% in the central portion of the substantia nigra and by 46% in the medial nigra but were unchanged in the lateral nigra (Table 4; Intrastriatal injections of 70 nmol quinolinic acid produced similar but smaller amounts of D, binding losses in either the caudoputamen or substantia nigra compared with the 125 nmol injections (Table 4) .
The intranigral injection of 6-hydroxydopamine in 5 rats produced a 70 f 14% (mean f SEM) decrease in the dopamine concentration of the lesioned caudateputamen (176 f 76 pmol! mg protein) compared to the dopamine concentration of the intact caudoputamen (587 f 33 pmol/mg protein; p < 0.01, Student's t test). Nevertheless, the 6-hydroxydopamine injections did not decrease the concentration of D, sites in either the caudoputamen or substantia nigra (Table 4) . This was the case even in 3 of these animals that showed a 90% or greater decrease in striatal dopamine levels (average lesioned hemisphere = 5 1 + 6 pmol/mg protein; intact hemisphere = 6 19 f 48 pmol/mg protein; p < 0.0 1, Student's t test). The equivalent binding of lZ51-SCH 23982 in the caudoputamen and substantia nigra of the left and right hemispheres in 1 of these animals is shown in (Table 4 ). However, in subsequent studies using longer (3 week) survival times and larger amounts (12 pg) of 6-hydroxydopamine that resulted in >90% depletions of striatal dopamine, we found no increase in 1Z51-SCH 23982 concentrations in the lateral portion of the substantia nigra of the denervated hemisphere (C. A. Altar and M. R. Marien, unpublished observations). As observed here at 1 week, virtually complete destruction of the nigrostriatal dopamine projection for 3 weeks was not associated with any change in 1251-SCH 23982 binding site concentrations in the caudateputamen.
Discussion
D, properties of lz51-SCH 23982 Progress in our understanding of the D, receptor and its function in brain has been accelerated by the recent discovery of selective D, receptor agonists and antagonists. 1251-SCH 23982 is likely to further accelerate the study of the D, receptor for several reasons. As shown here, 1Z51-SCH 23982 displayed a 55-125 PM affinity constant for the D, site in brain sections. This affinity is 5-to IO-fold higher than that obtained with 3H-SCH 23390 for the D, site in striatal homogenates (Billard et al., 1984; Schulz et al., 1985) . The higher affinity of lz51-SCH 23982 is probably not a result of differences in the properties of ligand binding to brain sections ahd homogenates. For example, lZ51-SKF 83692, the racemate of lZ51-SCH 23982, binds with a similar high affinity (& value of 100 PM) to D, sites in striatal homogenates (Sidhu and Kebabian, 1985) . Indeed, a correspondence in the affinities of a radiolabel for its binding site in homogenates and brain sections has many precedents in the literature, including 3H-tryptamine (Altar et al., 1985; Wood et al., 1984) , 3H-spiperone (Creese and Snyder, 1975; Palacios et al., 1981) , and 1251-LSD (Hartig et al., 1983; Nakada et al., 1984) . Another advantage of lZ51-SCH 23982 is its approximately 50-fold greater specific radioactivity compared with the tritiated D,-selective labels that are presently available. Autoradiography with the D, agonist 3H-SKF 38393 requires 3 weeks for image development (Scatton and DuBois, 1985) , and a similar period would probably be required for autoradiography with monotritiated SCH 23390. In contrast, 1251-SCH 23982 autoradiographs were produced in the present study in only 18 hr. The high affinity of lZ51-SCH 23982 for the D, receptor, when compared with this very high specific radioactivity, has allowed visualization of D, sites in the basal ganglia even when only a 500 fM concentration of the radioligand was used (C. A. Altar and M. R. Marien, unpublished observations).
Quantification of binding with iodinated standards prepared in our laboratory yielded B,,, values in the caudoputamen that were within an admittedly large range of B,,, values for the binding to striatal homogenates of3H-SCH 23390 (347 fmol/ mg protein: Schulz et al., 1985 ; 500 fmol/mg protein: Billard et al., 1984) and LZ51-SKF 83692 (12 fmol/mg protein: Sidhu and Kebabian, 1985) . A much lower affinity (& = 8 nM) and higher capacity (1250 fmol/mg protein) of 3H-SKF 38393 for the D, site has been reported (Scatton and DuBois, 1985) . Pharmacological displacement studies of 1251-SCH 23982 binding to sections revealed the same rank order of potency obtained by Sidhu and Kebabian (1985) using homogenates: with SCH (Scatton and DuBois, 1985) compared with D, antagonists (Billard et al., 1984; Sidhu and Kebabian, 1985) . In summary, the binding of lZ51-SCH 23982 to fresh-frozen rat brain sections and the digital quantification of the autoradiographic images reveal saturable and high-affinity binding of this ligand that is quantitatively and pharmacologically similar to D, binding to brain homogenates.
Localization and function of D, sites on striatonigral neurons The quinolinic acid-induced destruction of neurons that are intrinsic to the caudateputamen resulted in a marked (up to 87%) loss of D, sites in the striatum. These sites do not necessarily reside on striatonigral neurons. However, the concomitant loss (up to 58%) of D, sites in the substantia nigra most likely resulted from the degeneration of striatonigral cells following the destruction of their perikarya (Schwartz et al., 1982 (Schwartz et al., , 1984 . This demonstrates that the majority of D, binding sites in the substantia nigra reside on striatonigral neurons. Using similar quinolinic acid injection parameters but more resolute sampling of the substantia nigra, we (C. A. Altar and K. Hauser, unpublished observations) have discovered that up to 87% of the D, sites within subregions of the substantia nigra, pars reticulata are lost following lesions of the striatum that destroy virtually all (-98%) striatal D, sites. The failure of 6-hydroxydopamine-induced mesostriatal dopamine neuron losses of up to 94% to decrease the concentration of D, sites in either the striatum or substantia nigra demonstrates that few, if any, D, sites are intrinsic to mesostriatal dopamine neurons.
Each of these autoradiographic observations corroborates much of what is known about the D, receptor based on changes in either adenylate cyclase or its product, CAMP. Thus, dopamine-stimulated adenylate cyclase (DAC) is present in the rat neostriatum (Kebabian et al., 1972) and substantia nigra, pars reticulata (Gale et al., 1977; Kebabian and Saavedra, 1976) . These regions contained the highest concentrations of D, sites labeled with *251-SCH 23982. The dopamine receptor-adenylate cyclase complex is not on dopaminergic cells of the substantia nigra (Kebabian and Saavedra, 1976; Nagy et al., 1978) , and neither were the D, binding sites identified in the present experiments. Following destruction of mesostriatal dopaminergic neurons, the concentration of D, binding sites increased but only in the lateral substantia nigra. Following nigrostriatal lesions with kainic acid, Nagy and coworkers (1978) reported that levels of DAC per milligram of protein, but not per substantia nigra, increased in the lesioned substantia nigra. The marginal (p < 0.05) level of significance obtained for increases in the substantia nigra of DAC (Nagy et al., 1978) and D, concentrations (present results), and our subsequent failure to observe increases in D, concentrations in the striatum or nigra even 3 weeks after nigrostriatal denervation, indicates that D, receptors do not proliferate following dopamine denervation, at least not in the relatively rapid and robust manner demonstrable with D, autoradiography (Neve et al., 1984) or homogenate binding assays (Creese et al., 1983; Seeman et al., 1975) . In contrast, DAC in the substantia nigra and striatum is markedly decreased by lesions of the striatonigral pathway (Gale et al., 1977; Spano et al., 1977) and D, sites were greatly depleted in these areas following striatal injections with quinolinic acid. Of course, some striatal D, sites may reside on neurons that do not project to the nigra, and some nigral D, sites may reside on neurons that do not originate in the striatum. Nevertheless, because most D, sites in the caudoputamen and substantia nigra were lost after striatal cell destruction, and because of the preponderance of D, sites in these 2 areas, the striatonigral pathway is probably the major D, receptor-containing pathway in rat brain. That D, binding was also observed in the internal capsule is consistent with the well-characterized passage of striatonigral fibers through this fiber bundle (Garcia-Munoz et al., 1977; Marshall and Ungerstedt, 1977) . Whether D, sites in the region of the internal capsule represent receptor protein on the axonal membrane or are receptors in axonal transit is unknown.
Striatonigral neurons contain GABA (Jesse11 et al., 1978; Waddington and Cross, 1978; Guidotti et al., 1979) , substance P (Brownstein et al., 1977; Hong et al., 1977) and dynorphin B (Vincent et al., 1982; McLean et al., 1985) . Because the pattern of nigral D, binding losses following striatal lesions resembled almost exactly the topography of losses in dynorphin B or substance P concentrations (Kohno et al., 1984; McLean et al., 1985) , it is possible that D, receptors are on the terminals of substance P-or dynorphin B-containing striatonigral neurons. The absence of changes in the concentration of D, sites in the lateral substantia nigra following rostra1 striatal lesions may have been because the substance P input to this region is derived exclusively from the most posterior caudoputamen (Kohno et al., 1984) . In fact, we have recently shown that D, receptors in the lateral substantia nigra are also spared by striatal injections of quinolinic acid that produce neuronal toxicity restricted to the central region of the caudoputamen. Conversely, D, sites are lost in the lateral substantia nigra following quinolinic lesions that are restricted to the caudal caudoputamen (C. A. Altar and K. Hauser, unpublished observations) .
In what way is dopamine most likely able to stimulate D, receptors in the substantia nigra? The axon terminals of the striatonigral pathway are in direct synaptic contact with dopaminergic dendrites in the pars reticulata (Wassef et al., 1981) , but they may also form synaptic contacts in this brain region with serotonergic terminals (Gale, 1982) and GABAergic interneurons Bunney, 1979, 1985) . It is well established that dopamine is present in (Bjiirklund and Lindvall, 1975) and released from (Geffen et al., 1976; Korf et al., 1976; Nieoullon et al., 1977) dendrites of the nigrostriatal pathway. The coexistence in the pars reticulata of dendritically released dopamine, DAC, and D, binding sites suggests that dendritically released dopamine interacts with D, receptors to modulate adenylate cyclase in the terminals of striatonigral neurons. The presence of D, sites in the entopeduncular nucleus suggests that D, receptors may also mediate GABAergic striatoentopeduncular neurons (Pan et al., 1985) in a similar manner.
In conclusion, 1251-SCH 23982 is a selective radioligand with picomolar affinity for the D, receptor in brain sections. Its binding to the caudoputamen, nucleus accumbens, and olfactory tubercle is displaced by D, receptor agonists (SCH 23390, cisflupenthixol) and an antagonist (SKF 38393), but not by an S, antagonist (cinanserin) or by a D, agonist (LY 17 1555) or D, antagonist (I-sulpiride). D, sites are most concentrated in the medial substantia nigra but are also present in high concentration in the lateral substantia nigra, nucleus accumbens, olfactory tubercle, and caudoputamen. Lesser amounts of D, binding are present in the claustrum, sixth neocortical layer, internal capsule, and entopeduncular nucleus. The combination of chemical lesioning techniques and digital subtraction autoradiography has revealed for the first time the localization of D, binding sites to striatonigral neurons and not nigrostriatal neurons. The significance of D, receptors to the function of the striatoentopeduncular pathway or to GABAergic neurons of the striatonigral pathway has yet to be determined, as does the role of D, receptors in the regulation of substance P-or enkephalin B-containing neurons of the striatonigral projection.
